Rethinking Antibiotics: Can Our Body's Defenses Fight Infections Better?
"A new perspective on how phagocytes and antibiotics work together could change the way we treat common infections."
For many common infections, antibiotics are used to lessen discomfort rather than save lives, as the body's immune system often resolves the infection on its own. However, research and treatment strategies often overlook the significant role of natural defenses, such as phagocytosis, focusing primarily on antibiotics.
A recent study in Trends in Microbiology challenges this antibiotic-centered approach. It suggests that for acute, self-limiting infections—those the body can typically handle—optimizing our natural immune responses could be as important, or even more so, than relying solely on antibiotics. This could mean rethinking how we use these drugs, potentially leading to lower doses and reduced resistance.
This article will dive into the study's findings, exploring how a balanced approach that considers both antibiotics and the body's defenses could revolutionize the treatment of common bacterial infections.
Tracking Antimicrobial Resistance
The CDC says it uses several data sources and systems to track antimicrobial resistance in the United States and abroad. Its Antimicrobial Resistance & Patient Safety Portal brings together data from the National Healthcare Safety Network, the Antimicrobial Resistance Laboratory Network, and other sources, with visualizations covering resistance and antibiotic use. WHO’s AMR Data Portal provides human-health indicators for tracking national and global responses. ResistanceMap also summarizes national and subnational antimicrobial-use and resistance data worldwide and has done so since its launch in 2010.
Diagnostic Limits and Treatment Strategies
Culture-based methods for detecting antimicrobial resistance have limitations in sensitivity, turnaround time, and their ability to detect all potential resistance genes. A 2024 review describes these as shortcomings of current AMR detection techniques and an unmet clinical need. A separate review identifies vaccination, bacteriophage therapy, and antibiotics among the strategies used to combat resistant pathogens. These sources point to both diagnostic constraints and a wider set of approaches to resistance.
Resistance and Natural Selection
A history of antimicrobial resistance reports that Milislav Demerec showed antibacterial resistance could arise spontaneously in bacterial cultures through random genetic mutations. The mutations were not themselves a direct result of antibiotic exposure; rather, exposure selected resistant bacterial strains and allowed them to persist. A review of antibiotic resistance also covers the history of the antibiotics era, antibiotic modes of action, resistance mechanisms, and future strategies. Together, these accounts distinguish the emergence of resistance from the selection that antibiotics can exert.
The Overlooked Power of Our Internal Defenses
While the threat of antibiotic resistance is a serious concern, particularly for life-threatening infections in hospitals, it's crucial to remember that a significant portion of antibiotic use occurs in the community. These are often for infections that the body is capable of resolving on its own.
- Different Antibiotics, Similar Outcomes: When phagocytosis is highly effective, the study suggests that different types of antibiotics (bactericidal vs. bacteriostatic) might achieve similar results.
- Lower Doses, Equal Impact: In many cases, lower doses of antibiotics could be as effective as higher doses.
- Resistance Less Likely: Neither temporary (phenotypic) nor inherited antibiotic resistance is likely to cause treatment failure when phagocytosis is robust.
Models of Immunity and Antibiotic Treatment
A 2026 study reports that, in its model, the innate immune system was the primary factor in therapeutic success and could clear infections involving beta-lactamase-producing or ribosomal mutant-resistant strains. A separate study found that sufficiently high bacterial densities could saturate innate immunity. It also reported that bacteriostatic drugs and bacteriophages were as effective as bactericidal antibiotics in preventing mortality and controlling bacterial densities, and that minority populations resistant to a treating antibiotic did not ascend. These are findings from the studies’ models and analyses, not a general guarantee of outcomes in patients.
Obstacles to New Antibiotics
A review describes the search for new antibiotics and other antimicrobials as a pressing need in the fight against bacterial infections. It also reports that antibiotic resistance appears inevitable and that pharmaceutical-industry investment in new antibiotic research has remained limited. Another review evaluates limitations of conventional antibiotics, failures of traditional discovery pipelines, and the clinical and economic burden of resistant infections. A separate review points to beta-lactamase inhibitors, efflux-pump inhibitors, and outer-membrane permeabilizers as potential antibiotic adjuvants to address resistance.
Toward Smarter Antibiotic Use
The study's model highlights the potential for a more nuanced approach to antibiotic therapy. By acknowledging and harnessing the power of the body's natural defenses, we can potentially reduce our reliance on antibiotics, minimizing the risk of resistance and side effects.
The Host’s Role in Acute Infections
A 2017 review says most antibiotic use in humans is intended to reduce the magnitude and duration of illness from acute, community-acquired infections in immune-competent patients, rather than to save lives. It notes that phagocytic leukocytes and other host defenses make the vast majority of these infections self-limiting. The authors also say the contribution of phagocytosis to antibiotic treatment had received negligible consideration. This perspective highlights host defenses as part of the context in which antibiotic treatment works.
Renewed Interest in Phage Therapy
A 2026 review examines the resurgence of bacteriophage therapy as a precision strategy for multidrug-resistant bacterial infections. It critically reviews phage biology and the challenges involved in applying the approach. The review also calls for reconsidering phage therapy and discusses its mechanisms and applications. The source presents phage therapy as an area of renewed attention, rather than establishing it as a settled replacement for antibiotics.
Incentives and AMR’s Wider Drivers
A 2026 review argues that incentivizing development of new antibiotics is critical, especially for multidrug-resistant Gram-negative pathogens. It identifies scientific and economic challenges facing the pharmaceutical industry and describes public–private partnerships and market-entry rewards as push–pull mechanisms to stimulate innovation. A 2024 review describes antimicrobial resistance as a critical global health issue driven by antibiotic misuse and overuse across various sectors, contributing to resistant microorganisms. Together, these sources emphasize both innovation incentives and broader patterns of antibiotic use.
This isn't about abandoning antibiotics altogether, but rather using them more strategically. For self-limiting infections in healthy individuals, a focus on supporting the immune system might be just as effective as a heavy dose of antibiotics.
Further research is needed to refine our understanding of the interplay between antibiotics and the immune system. Studies involving animal models and human clinical trials can help determine the optimal strategies for treating various infections while minimizing the development of antibiotic resistance.